CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. [Read more…]
U.S. FDA Grants Approval of Fourth CAR-T Cell Therapy (Breyanzi) to Juno Therapeutics
On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
Is Storing Your Immune Cells Really Worth It?
While cryopreserving cell tissue, stem cells and other blood products is nothing novel, the emerging field of immune cell banking certainly is. Immune cells are all the cells that make up your immune system, including T-cells, B-cells, NK cells, neutrophils cells, monocytes, dendritic cells, etc. They are your body’s first line of defense against infection and disease. New immunotherapies, such as CAR T-cell, CAR NK and dendritic cell therapies, are currently being developed to leverage those cells and offer new, experimental treatment options for cancer patients.
Storing immune cells may be a fairly new concept, but the potential benefits of storing immune cells have made forward-thinking, health-conscious individuals take notice. [Read more…]
Ushering in the Era of CAR-T: Kymriah, Yescarta, and Tecartus
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” [Read more…]
Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control
In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.
The pace never slows when your mission is to enable lifesaving science! [Read more…]
